XENE - Xenon Pharmaceuticals Inc. (XENE) Q1 2024 Earnings Call Transcript

2024-05-09 20:05:29 ET

Xenon Pharmaceuticals Inc. (XENE)

Q1 2024 Earnings Conference Call

May 9, 2024, 4:30 PM ET

Company Participants

Chad Fugere - Vice President, Investor Relations

Ian Mortimer - President and CEO

Dr. Chris Kenney - Chief Medical Officer

Dr. Chris Von Seggern - Chief Commercial Officer

Sherry Aulin - Chief Financial Officer

Conference Call Participants

Paul Matteis - Stifel

Leo Timashev - RBC Capital Markets

Jason Gerberry - Bank of America

Luke Hermann - Baird

Tess Romero - JPMorgan

Khalil Fenina - Goldman Sachs

Alex Nackenoff - Raymond James

Basma Radwan - Leerink

Andrew Tsai - Jefferies

Peyton Bohnsack - TD Cowen

Tim Lugo - William Blair

Mohit Bansal - Wells Fargo

David Huang - Citigroup

Presentation

Operator

Thank you for standing by. My name is Liz, and I’ll be your conference operator today. At this time, I’d like to welcome everyone to the First Quarter 2024 Xenon Pharmaceuticals Incorporated Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker remarks, there will be a question-and-answer session. [Operator Instructions]

Thank you. I’d now like to turn the call over to Chad Fugere, VP, Investor Relations. Please go ahead.

Chad Fugere

Thank you, Operator, and good afternoon. Thank you for joining us on our call and webcast to discuss Xenon’s first quarter 2024 financial and operating results. Joining me today are Ian Mortimer, Xenon’s President and Chief Executive Officer; Dr. Chris Kenney, Xenon’s Chief Medical Officer; Dr. Chris Von Seggern, Xenon’s Chief Commercial Officer; and Sherry Aulin, Xenon’s Chief Financial Officer.

Ian will begin with a summary of our recent progress, Chris Kenney will provide an overview of our ongoing clinical stage program, including our plans and major depressive disorder or MDD, Chris Von Seggern will summarize key findings from recently completed market research, and Sherry Aulin will close with a summary of our financial results and anticipated milestone events before opening the call up to your questions.

Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding the timing of and potential results from clinical trials, the potential efficacy, safety profile, future development plans and current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners’ product candidates, the efficacy of our clinical trial design, our ability to successfully develop and achieve milestones in our clinical development program, the timing and results of our interactions with regulators, our ability to successfully develop and obtain regulatory approvals, anticipated enrollment in our clinical trials and the timing thereof, and our expectation that we will have sufficient cash to fund operations into 2027.

Today’s press release summarizing Xenon’s first quarter 2024 financial results and the accompanying quarterly report on Form 10-Q will be made available under the Investor Section of our website at xenon-pharma.com and filed with the SEC and on SEDAR+.

Now, I would like to turn the call over to Ian. Ian?

Ian Mortimer

Thank you, Chad, and good afternoon, everyone, and thanks for joining us on our call today. Before I provide an update on our pipeline, I’m excited to announce that we have received approvals from the United States Adopted Names, or USAN Council and the World Health Organization International Nonproprietary Names, or INN Expert Committee for the use of azetukalner as the nonproprietary or generic name for XEN1101....

For further details see: